Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models.
Peng X, Hou P, Chen Y, Dai Y, Ji Y, Shen Y, Su Y, Liu B, Wang Y, Sun D, Jiang Y, Zha C, Xie Z, Ding J, Geng M, Ai J.
Peng X, et al. Among authors: chen y.
J Exp Clin Cancer Res. 2019 Aug 22;38(1):372. doi: 10.1186/s13046-019-1357-y.
J Exp Clin Cancer Res. 2019.
PMID: 31438996
Free PMC article.